Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment2.62%+0.68 ppManaged Health Care0.94%-0.32 ppBiotechnology1.86%+0.26 ppLife Sciences Tools & Services0.91%-0.18 ppPharmaceuticals3.59%+0.17 ppHealth Care Distributors0.43%+0.14 ppHealth Care Services0.49%+0.07 ppHealth Care Facilities0.21%+0.04 ppHealth Care Supplies0.09%-0.02 ppHealth Care Technology0.03%+0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.86%
Industry change · 12M
+0.26 pp
Biotechnology · contribution
+0.259 pp
Company participation
13%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
May 2025 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $328.7bn | 0.745% | -0.080 pp | +0.201 pp | +19.6% | No |
| Gilead Sciences → GILD | United States | $136.9bn | 0.310% | -0.008 pp | +0.157 pp | +77.7% | Yes |
| Moderna → MRNA | United States | $10.3bn | 0.023% | -0.003 pp | -0.081 pp | -81.4% | No |
| Regeneron Pharmaceuticals → REGN | United States | $46.1bn | 0.104% | -0.042 pp | -0.072 pp | -49.8% | No |
| Amgen → AMGN | United States | $155.0bn | 0.351% | -0.019 pp | +0.037 pp | -2.7% | No |
| Vertex Pharmaceuticals → VRTX | United States | $113.5bn | 0.257% | -0.018 pp | +0.033 pp | -2.9% | No |
| Biogen → BIIB | United States | $19.0bn | 0.043% | -0.003 pp | -0.020 pp | -42.3% | No |
| Incyte → INCY | United States | $12.6bn | 0.029% | -0.003 pp | +0.004 pp | +12.6% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.